FSH Blood Test Explained: What It Measures and Why It's Requested

Follicle-stimulating hormone (FSH) is one of the most frequently measured reproductive hormones in clinical laboratories. This page summarises the published literature on the analyte itself, how it is measured, the clinical situations in which testing is described, and the assay characteristics that complicate interpretation. This page is for educational purposes only and is not medical advice; consult a licensed physician or the clinician who requested the test about any individual laboratory value.

What FSH Is and Where It Comes From

FSH is a glycoprotein hormone synthesised and secreted by gonadotroph cells of the anterior pituitary gland, under the control of hypothalamic gonadotropin-releasing hormone (GnRH) and feedback from gonadal steroids and peptides. It shares a common alpha subunit with luteinising hormone (LH), thyroid-stimulating hormone and human chorionic gonadotropin, and carries a hormone-specific beta subunit. A comprehensive review of the definition and measurement of FSH described the hormone as a family of closely related molecules rather than a single uniform species, because carbohydrate side chains differ between circulating forms and influence both receptor activity and clearance (PMID 10696567).

In females, FSH acts on granulosa cells of the ovarian follicle, supporting follicular recruitment and growth and aromatase activity. In males, FSH acts on Sertoli cells within the seminiferous tubules, where it contributes to the support of spermatogenesis. Because Sertoli cells also secrete anti-Müllerian hormone (AMH) and inhibin B, several published diagnostic studies in boys evaluated FSH alongside those Sertoli cell markers rather than in isolation (PMID 22570945).

What the FSH Blood Test Measures

The routine FSH test is performed on serum or plasma obtained by venipuncture and reports an immunoreactive concentration, conventionally expressed in international units per litre. The review of FSH definition and measurement distinguished bioassays, which measure biological activity at the receptor, from immunoassays, which detect epitopes on the molecule, and noted that the two approaches do not always agree because immunologically detectable material is not necessarily biologically active (PMID 10696567).

Assay formats and standardisation

Modern clinical laboratories generally use two-site immunometric ("sandwich") assays with chemiluminescent, fluorescent or enzymatic detection on automated platforms. The same review described calibration against international reference preparations as central to comparability between laboratories, and reported that differences in antibody specificity and in the reference material used help explain why results from different assays are not freely interchangeable (PMID 10696567).

Isoforms and glycosylation

FSH circulates as a mixture of isoforms that differ in sialic acid content and isoelectric point. Researchers who examined the FSH isoform pattern in classic galactosemia reported that the glycosylation and isoform distribution of circulating FSH was a subject of specific investigation in that inherited metabolic disorder, which is associated with primary ovarian insufficiency (PMID 20814826). Taken together with the measurement review, this literature illustrates that a single numerical FSH concentration summarises a heterogeneous population of molecules (PMID 10696567).

Why Clinicians Request FSH Testing, as Described in the Literature

Published clinical studies describe FSH measurement in several recurring contexts. In each case the test is reported as one input among several, typically interpreted alongside LH, oestradiol or testosterone, AMH, clinical history and imaging.

Ovarian reserve and premature ovarian insufficiency

A review of premature ovarian insufficiency (POI) and the associated fertility challenge described the condition as a loss of ovarian function before the age of 40 characterised by menstrual disturbance with elevated gonadotropin concentrations, and discussed the consequences for fertility management (PMID 24848073). Gonadotropin measurement therefore appears in the diagnostic description of POI rather than as a standalone screening test.

Ovarian reserve has also been studied in relation to environmental exposures. A single-centre study reported that higher serum bisphenol S levels were associated with decreased ovarian reserve function in the women studied (PMID 39544747). The study was observational, so the researchers described an association rather than a demonstrated cause.

Polycystic ovary syndrome evaluation

In suspected PCOS, gonadotropins are generally measured as part of a wider panel used to exclude alternative explanations for anovulation. A study of AMH levels in PCOS phenotype D examined how AMH performed as a diagnostic marker within that specific phenotype (PMID 41519190). Separately, researchers applying machine-learning algorithms reported that oviduct glycoprotein 1 (OVGP1) was evaluated as a candidate diagnostic marker for PCOS (PMID 39713694). Both lines of work reflect ongoing efforts to supplement, rather than replace, conventional hormone panels.

Delayed, absent or early puberty

Paediatric endocrinology accounts for a substantial share of published FSH testing research. A 2025 study reported that FSH together with Sertoli cell biomarkers accurately distinguished hypogonadotropic hypogonadism from self-limited delayed puberty in boys presenting with delayed pubertal onset (PMID 39930628). An earlier paper examined Sertoli cell markers in the diagnosis of paediatric male hypogonadism and described their role alongside gonadotropins (PMID 22570945).

At the opposite end of the spectrum, researchers evaluated screening for central precocious puberty using a single basal LH measurement, reporting on how that simplified approach compared with stimulation-based assessment (PMID 38507183). A further study reported on serum MBD3 as a candidate marker in girls with central precocious puberty (PMID 37426049). Because FSH and LH behave differently across developmental stages, the ratio between them has itself been studied: a 2022 analysis described dynamic changes in LH/FSH ratios in infants with normal sex development (PMID 35521767).

Male reproductive assessment

In adult men, FSH is described in the literature as part of the hormonal assessment of impaired spermatogenesis, used together with LH, testosterone and semen analysis. Animal work has explored upstream influences on male fertility from other directions; a 2023 study in sheep used microbiome–metabolome analysis to examine the contribution of the gut–testis axis to sperm motility (PMID 36978536). Findings in sheep do not transfer directly to humans.

What Published Studies Associate With High and Low Values

The literature links FSH concentrations to the integrity of the hypothalamic–pituitary–gonadal axis rather than to a single disease. The table below summarises directions of association as described in the cited papers; it is not a reference range and does not apply to any individual.

Broadly, the published pattern is that gonadotropins rise when gonadal feedback falls (primary gonadal failure) and remain low or inappropriately normal when the pituitary or hypothalamus is the limiting step, as reflected in the paediatric diagnostic work on hypogonadotropic hypogonadism (PMID 39930628). Whether a given value fits either pattern is a clinical judgement that belongs to the clinician who requested the test.

Assay and Interpretation Caveats: What Studies Report

Several documented factors complicate the reading of a single FSH number.

• Molecular heterogeneity. The measurement review reported that FSH exists as multiple glycoforms with differing bioactivity and clearance, so immunoassay concentration and biological effect are not identical quantities (PMID 10696567).
• Assay-to-assay variation. The same review described how differences in antibodies, calibrators and reference preparations contribute to discrepancies between methods (PMID 10696567), which is why laboratories report method-specific intervals.
• Disease-specific isoform changes. Researchers investigating classic galactosemia examined the FSH isoform pattern specifically, indicating that the composition of circulating FSH can differ in particular conditions (PMID 20814826).
• Age and developmental stage. The infant LH/FSH ratio study reported that gonadotropin relationships change dynamically during early life in children with normal sex development (PMID 35521767), so adult-oriented thinking does not transfer to paediatric samples.
• Single versus stimulated sampling. Work on screening for central precocious puberty evaluated whether a single basal gonadotropin measurement could substitute for stimulation testing (PMID 38507183), illustrating that sampling strategy itself affects diagnostic performance.
• Companion markers. Studies of AMH in PCOS phenotype D (PMID 41519190) and of Sertoli cell markers in paediatric male hypogonadism (PMID 22570945) reported that gonadotropins were interpreted together with other analytes rather than alone.

How the Literature Frames Interpretation

Across these papers, FSH appears as a context-dependent signal. The same concentration can carry different meaning depending on age, sex, pubertal stage, menstrual cycle phase, concurrent medication, the assay platform used, and the clinical question being asked. No study in this set proposed that a single FSH value, read in isolation, established a diagnosis; the diagnostic papers consistently paired it with other markers or with clinical assessment (PMID 39930628, PMID 22570945).

For that reason, this page does not provide reference intervals, thresholds or interpretations. Laboratories publish method-specific intervals with their reports, and the meaning of a result for a particular person is determined by the clinician who requested the test in light of the full clinical picture. Anyone with questions about a laboratory report should raise them with a licensed physician.

References

• Definition and measurement of follicle stimulating hormone (Endocrine Reviews, 2000)
• Premature ovarian insufficiency - fertility challenge (Minerva Ginecologica, 2014)
• FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty (The Journal of Clinical Endocrinology and Metabolism, 2025)
• Sertoli cell markers in the diagnosis of paediatric male hypogonadism (Journal of Pediatric Endocrinology & Metabolism, 2012)
• Screening for central precocious puberty by single basal Luteinizing Hormone levels (Endocrine, 2024)
• FSH isoform pattern in classic galactosemia (Journal of Inherited Metabolic Disease, 2011)
• Dynamic changes in LH/FSH ratios in infants with normal sex development (European Journal of Endocrinology, 2022)
• AMH levels and diagnosis in PCOS phenotype D (Clinical Biochemistry, 2026)
• Oviduct Glycoprotein 1 (OVGP1) Diagnoses Polycystic Ovary Syndrome (PCOS) Based on Machine Learning Algorithms (ACS Omega, 2024)
• Serum bisphenol S levels are associated with decreased ovarian reserve function: a single-center study (American Journal of Translational Research, 2024)
• Clinical significance of serum MBD3 detection in girls with central precocious puberty (Open Medicine, 2023)
• Microbiome-Metabolome Reveals the Contribution of the Gut-Testis Axis to Sperm Motility in Sheep (Ovis aries) (Animals, 2023)